Switzerland

BMI View: For innovative drugmakers, the importance of maintaining healthy research and development (R&D) pipelines and launching new drugs cannot be stressed enough. The 'patent... 2013-01-24

BMI View: The patent expiry of Novartis' Diovan in the US will affect sales through to 2013 due to potential generic competition. However, as we expect strong growth from emerging markets,... 2012-10-31

BMI View: Roche's focus on diagnostics and oncology-related products will allow it to outperform its multinational rivals. The Swiss firm's biologics pipeline will ensure strong growth... 2012-10-18

BMI View: The patent expiry of Diovan (valsartan) in the US in 2012, continuing falling revenue due to generic competition to Diovan in Europe and the lower sales expectations for Rasilez/Tekturna... 2012-07-23

BMI Core View: The uptake of generic drugs following patent expiry will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which... 2012-05-08

BMI View: The patent expiry of Diovan (valsartan) in the US in 2012, continuing falling revenue due to generic competition to Diovan in Europe and the lower sales expectations for Rasilez/Tekturna... 2012-04-25

BMI View: The expected growth of the Switzerland's ageing population over the next 50 years is to have an unprecedented impact on the demand for healthcare. The elderly require more... 2011-11-30